Bristol-Myers Squibb Company
430 E. 29th St
14th Floor
New York
New York
10016
United States
Tel: 212-546-4000
Fax: 212-546-4020
Website: http://www.bms.com/
About Bristol-Myers Squibb Company
Bristol-Myers Squibb is a global biopharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Join us at the Spring 2019 Genetown Talent Connect in Boston, MA. Click here to register today!
2003 articles with Bristol-Myers Squibb Company
-
Bristol-Myers Squibb Announces Time Change for Q4 Earnings Results Conference Call
1/24/2019
Bristol-Myers Squibb Company announced today that its fourth quarter 2018 earnings call has been rescheduled for two hours earlier than previously announced.
-
It’s no secret that the pharmaceutical industry spends a significant amount of money lobbying state and federal governments to gain leverage that will benefit individual companies and the industry overall.
-
Any 2018 BMS news is going to tend to get lost in the shadow of its $74 billion acquisition of Celgene. Still, it looked like a good year, with fourth-quarter revenue up 10% and full-year revenues up 9%.
-
Now that Bristol-Myers Squibb is acquiring Celgene, the company will largely disappear into Bristol-Myers Squibb, but a legacy of bold risk-taking and questionable price hikes remain.
-
Nonalcoholic steatohepatitis (NASH) is prevalent in the U.S. and developing countries, but under that name, is largely unknown to the general public. NASH is a liver disease similar to cirrhosis, but which occurs in people who drink little or no alcohol.
-
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
-
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
-
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
1/14/2019
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved the combination of Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (“low-dose”) for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
-
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
-
It's a new year! Is one of your New Year's resolutions to find a new job? Jump start your job search now and check out top companies who are looking for quality candidates in 2019!
-
Bristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare Conference
1/5/2019
Bristol-Myers Squibb Company today announced that Giovanni Caforio, M.D., chairman and chief executive officer, will join Mark Alles, chairman and chief executive officer of Celgene, for a fireside chat at the 37th Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT (10:30 a.m. ET) on Monday, January 7, 2019 at the Westin St. Francis in San Francisco.
-
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
-
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of Celgene Corporation; Are Celgene Shareholders Getting a Fair Deal?
1/3/2019
Johnson Fistel, LLP has launched an investigation into whether the board members of Celgene Corporation breached their fiduciary duties in connection with the proposed sale of the Company to Bristol-Myers Squibb Company
-
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
1/3/2019
Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease
-
Bristol-Myers Squibb Provides 2019 EPS Guidance
1/3/2019
Bristol-Myers Squibb Company today announced EPS guidance for full-year 2019.
-
Bristol-Myers Squibb will acquire Celgene Corporation to create a pharma giant with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease.
-
Bristol-Myers Squibb’s Sprycel® (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
1/2/2019
Sprycel is the first and only second-generation tyrosine kinase inhibitor for pediatric patients for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia in combination with chemotherapy
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
Bristol-Myers Squibb and H3 Biomedicine Announce Research Collaboration to Advance Novel Therapeutics Leveraging H3’s RNA Splicing Platform
12/17/2018
Bristol-Myers Squibb Company (NYSE: BMY), Eisai Co., Ltd. and its U.S.-based precision medicine research & development subsidiary H3 Biomedicine Inc. (Massachusetts, “H3”) today announced a multi-year research collaboration focused on evaluating whether novel therapeutics leveraging H3’s RNA splicing platform can provide a more powerful response against cancer.
-
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Sprycel (dasatinib) for Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
12/17/2018
Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the expanded approval of Sprycel (dasatinib), in combination with chemotherapy, to include the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).